Corporate Profile

Incyte’s mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.  For additional information on Incyte, please visit the Company’s website at www.incyte.com.


Recent News More >>
DateTitle 
March 17, 2015Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that Novartis received approval from the European Commission for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and L... 
Printer Friendly Version
March 02, 2015Incyte Appoints Steven H. Stein, MD as Chief Medical Officer
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 2, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that Steven H. Stein, MD, has been appointed Senior Vice President and Chief Medical Officer, effective immediately. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte’s extensive oncology portfolio. Steve... 
Printer Friendly Version
February 26, 2015Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera – a Rare, Progressive Blood Cancer
Results expected to provide better strategies for both patients and physicians to manage the burden of this disease WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 26, 2015-- Incyte Corporation (Nasdaq: INCY) today announced that it is sponsoring the first major observational study of patients living with polycythemia vera (PV) in the U.S. PV is a rare and progressive blood cancer that can lead to debilitating symptoms, serious cardiovascular complications, ... 
Printer Friendly Version

2013 Annual Report
2013 Annual Report Download Documentation

2013 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.